Advanced
Synthesis and Biological Evaluation of Curcumin Analogs as Antiplatelet Inhibitor
Synthesis and Biological Evaluation of Curcumin Analogs as Antiplatelet Inhibitor
Bulletin of the Korean Chemical Society. 2014. May, 35(5): 1537-1540
Copyright © 2014, Korea Chemical Society
  • Received : December 30, 2013
  • Accepted : January 07, 2014
  • Published : May 20, 2014
Download
PDF
e-PUB
PubReader
PPT
Export by style
Article
Author
Metrics
Cited by
TagCloud
About the Authors
Dong Won Lee
Department of Organic Synthesis, Shinpoong Pharmaceutical Co., LTD, Ansan 434-4, Korea.
Jin Hun Park
Department of Organic Synthesis, Shinpoong Pharmaceutical Co., LTD, Ansan 434-4, Korea.
Seung Soo Yoon

Abstract
Keywords
PPT Slide
Lager Image
PPT Slide
Lager Image
PPT Slide
Lager Image
Experimental
Preparation of Platelets. Whole blood for experiment was collected from abdominal aorta in male SD rat. And it was anticoagulated with 1 mL of 3.2% sodium citrate solu-tion for the preparation of platelet rich plasma (PRP) and pletelets were activated in the presence of 100 μL of PGE 1 for the preparation of washed platelets (WPs). PRP was prepared by centrifugation for 15 min at 150 g, and platelet-poor plasma was obtained from the precipitated fraction of PRP by centrifugation for 20 min at 2000 g. The platelet count in PRP was adjusted to 1 × 10 8 cells/mL by using platelet-poor plasma. For preparation of WPs, PRP was centrifuged for 10 min at 500 g, and platelet pellets were washed in Tyrode buffer.
Measurement of Aggregation. Washed platelets were adjusted to 1 × 10 8 cells/mL with suspension buffer . After incubation with 10 mM of each compound for 3 min at 37 °C, 500 μL of suspention buffer was loaded on the aggrego-meter and stimulated 20 μL of thrombin (20 u/mL), 20 μL of ADP (1 mM) and 20 μL of collagen (1 mg/mL). Platelet aggregation was measured by light transmission.
Purification of Curcumin and Bisdemethoxycurcumin from Commercial Curcumi-noids. A solution of curcuminoids (5.0 g) in ethanol (50 mL) was heated under reflux for 1 h and the mixture was cooled to room temperature and filtered and washed with a small amount of ethanol. 2.6 g of curcumin was obtained and the mother liquid was concen-trated under reduced pressure. 50 mL of dichloromethane was added to the residue and heated under reflux for 1 h. The mixture was cooled to room temperature, filtered, and washed with a small amount of dichloromethane. 1.1 g of bisdemethoxycurcumin was obtained.
Synthesis of (1E,6E)-1,7-Bis(4-cyclopentyloxy-3-meth-oxyphenyl)-1,6-heptadiene-3,5-dione (2c) (General pro-cedure). Cyclopentanecarbonyl chloride (1.0 mL, 8.14 mmol) was added to a solution of curcumin (1.0 g, 2.71 mmol) and TEA (1.1 mL, 8.14 mmol) in acetone (10 mL). The reaction mixture was stirred at 0 °C for 0.5 h. The mixture was quenched with water (30 mL) and extracted with EtOAc (30 mL). The combined organic layer was washed with brine, dried over anhydrous MgSO 4 , filtered, and concentrated under reduced pressure. EtOH was added to the residue and stirred overnight at room temperature. The formed solid was filtered and washed with a small amount of EtOH and dried under vacuum at 40 °C. 0.9 g of the title compound was obtained as a dark yellow solid. (yield 66%) 1 H NMR (400 MHz DMSO- d 6 ) δ 7.66 (d, J = 16.0 Hz, 2H), 7.52 (s, 2H), 7.33 (dd, J = 1.6 and 1.2 Hz, 2H), 7.15 (d, J = 8.0 Hz, 2H), 7.00 (d, J = 16.0 Hz, 2H), 6.20 (s, 1H), 3.84 (s, 6H), 3.08-3.01 (m, 2H), 2.00-1.84 (m, 8H), 1.70-1.64 (m, 8H); 13 C NMR δ 183.7, 174.4, 151.7, 141.6, 140.3, 134.1, 125.0, 123.7, 121.9, 122.5, 102.2, 56.5, 43.2, 30.0, 25.9; Mass m/z 561.6 [M+1].
Synthesis of Pentanedioic Acid Mono-(4-{7-[4-(4-carboxybutyryl-oxy)-3-methoxy-phenyl]-3,5-dioxo-hepta-1,6-di-enyl}-2-methoxyphenyl) (2d) (General procedure). Glutaric anhydride (0.93 g, 8.14 mmol) was added to a solution of curcumin (1.0 g, 2.71 mmol) and TEA (1.1 mL, 8.14 mmol) in dichloromethane (10 mL). The reaction mixture was stirred overnight at room temperature and then concentrated under reduced pressure. EtOAc (20 mL) and water (20 mL) were added to the residue, and the pH of the mixture was adjusted to 4 by dropwise addition of conc. HCl. The combined organic layer extracts were dried over anhydrous MgSO 4 , filtered, and concentrated under reduced pressure. IPA (10 mL) was added to the residue and water was added dropwise until a solid was formed. The mixture was stirred overnight at room temperature. The formed solid was filter-ed and washed with a small amount of IPA and dried under vacuum at 40 °C. 1.0 g of the title compound was obtained as a dark yellow solid. (yield 31%) 1 H NMR (400 MHz DMSO- d 6 ) δ 12.15 (brs, 2H), 7.66 (d, J = 16.0 Hz, 2H), 7.33 (dd, J = 1.6 and 1.2 Hz, 2H), 7.17 (d, J = 8.0 Hz, 2H), 7.00 (d, J = 16.0 Hz, 2H), 6.21 (s, 1H), 3.87 (s, 1H), 2.63 (t, J = 7.2 Hz, 4H), 2.37 (t, J = 7.2 Hz, 4H), 1.87 (p, J = 7.2 Hz, 4H); 13 C NMR δ 183.7, 174.5, 171.2, 151.6, 141.4, 140.3, 134.2, 125.1, 123.8, 121.9, 112.5, 54.5, 32.9, 29.8, 20.5; Mass m/z 597.3 [M+1].
Synthesis of 4-{3,5-Bis-[2-(4-hydroxy-3-methoxy-phenyl)-vinyl]-pyrazol-1-yl}-benzenesulfonamide (4b) (General procedure). Catalytic amount of acetic acid was added to a solution of curcumin (10.0 g, 27.1 mmol) and 4-hydrazino-benzenesulfonamide hydrochloride (12.0 g, 54.3 mmol) in EtOH (100 mL). The reaction mixture was heated under reflux for 6 h and cooled to room temperature. The formed solid was filtered and washed with a small amount of EtOH and dried overnight under vacuum at 40 °C. 13.7 g of the title compound was obtained as a yellow solid. (Yield 82%) 1 H NMR (400 MHz, DMSO- d 6 ) δ 8.00 (d, J = 8.8 Hz, 2H), 7.77 (d, J = 8.8 Hz, 2H), 7.50 (s, 2H), 7.25-7.15 (m, 4H), 7.12 (s, 1H), 7.05 (d, J = 16.0 Hz, 1H), 7.02-6.99 (m, 2H), 6.88 (d, J = 16.0 Hz, 1H), 6.80 (dd, J = 1.2 and 1.6 Hz, 2H), 3.85 (s, 3H), 3.81 (s, 3H); 13 C NMR δ 152.33, 148.4, 148.3, 148.0, 147.5, 143.3, 142.9, 142.2, 134.1, 131.9, 128.9, 128.7, 128.2, 127.5, 125.1, 124.9, 121.0, 120.9, 117.5, 111.8, 111.3, 110.1, 102.2, 56.2, 56.1; Mass m/z 520.5 [M+1].
(1E,6E)-1,7-Bis(4-hydroxy-3-methoxyphenyl)-1,6-hept-adiene- 3,5-dione (1a): 1 H NMR (400 MHz, DMSO- d 6 ) δ 9.68 (brs, 2H), 7.55 (d, J = 15.6 Hz, 2H), 7.33 (d, J = 1.6 Hz, 1H), 7.16 (d, J = 8.4 Hz, 2H), 6.83 (d, J = 8.4 Hz, 2H), 6.76 (d, J = 16.0 Hz, 2H), 6.06 (s, 1H), 3.84 (s, 6H); 13 C NMR δ 183.7, 149.8, 148.4, 141.2, 126.8, 123.6, 121.5, 116.2, 111.8, 101.3, 56.1.
(1E,6E)-1,7-Bis(4-hydroxyphenyl)-1,6-heptadiene-3,5-dione (1b): 1 H NMR (400 MHz, DMSO- d 6 ) δ 10.06 (brs, 2H), 7.58-7.53 (m, 6H), 6.82 (d, J = 8.4 Hz, 4H), 6.70 (d, J = 16.0 Hz, 2H), 6.04 (s, 1H); 13 C NMR δ 183.7, 160.3, 140.8, 130.8, 126.3, 121.2, 116.4, 101.5.
(1E,6E)-1,7-Bis(4-cyclohexyloxy-3-methoxyphenyl)-1,6-heptadiene-3,5-dione (2a): 1 H NMR (400 MHz CDCl 3 ) δ 7.61 (d, J = 16.0 Hz, 2H), 7.16-7.02 (m, 6H), 6.56 (d, J = 16.0 Hz, 2H), 5.85 (s, 1H), 3.86 (s, 6H), 2.65-2.58 (m, 2H), 2.17-2.06 (m, 4H), 1.85-1.82 (m, 4H), 1.71-1.58 (m, 6H), 1.42-1.32 (m, 6H); 13 C NMR δ 183.1, 173.9, 151.5, 141.7, 140.0, 133.7, 124.1, 123.3, 122.2, 121.1, 111.5, 101.8, 55.9, 43.0, 29.0, 25.8, 25.3; Mass m/z 589.6 [M+1].
(1E,6E)-1,7-Bis-(4-furyloxy-3-methoxyphenyl)-1,6-hepta-diene-3,5-dione (2b): 1 H NMR (400 MHz, CDCl 3 ) δ 7.68 (s, 2H), 7.64 (d, J = 16.0 Hz, 2H), 7.41 (d, J = 3.6 Hz, 2H), 7.18 (s, 4H), 7.16 (s, 2H), 6.60-6.57 (m, 4H), 5.87 (s, 1H), 3.87 (s, 1H); 13 C NMR δ 183.1, 156.2, 151.6, 147.2, 143.7, 140.7, 139.9, 134.3, 124.4, 123.4, 121.1, 119.8, 112.3, 111.6, 101.9, 56.0; Mass m/z 557.7 [M+1].
1,7-Bis-[4-(4-4-methyl-piperazin-1-ylmethyl-benzoyloxy)-3-methoxyphenyl]-hepta-1,6-diene-3,5-dione (2e): 1 H NMR (400 MHz CDCl 3 ) δ 8.17 (d, J = 8.0, 4H), 7.67 (d, J = 16.0, 2H), 7.50 (d, J = 8.0, 4H), 7.28-7.18 (m, 6H), 6.61 (d, J = 16.0, 2H), 5.90 (s, 1H), 3.88 (s, 3H), 3.62 (s, 4H), 2.53 (brs, 16H), 2.34 (s, 6H); 13 C NMR δ 183.1, 164.5, 151.7, 144.7, 141.6, 140.0, 134.0, 130.4, 129.1, 127.9, 124.3, 123.5, 121.2, 111.6, 101.9, 62.6, 56.0, 55.1, 53.0, 46.0; Mass m/z 801.4 [M+1].
(1E,6E)-1,7-Bis(4-cyclopentyloxyphenyl)-1,6-heptadiene-3,5-dione (3): 1 H NMR (400 MHz DMSO- d 6 ) δ 7.72 (d, J = 8.4 Hz, 4H), 7.65 (d, J = 16.0 Hz, 2H), 7.19 (d, J = 8.8 Hz, 4H), 6.83 (d, J = 16.0 Hz, 2H), 6.20 (s, 1H), 3.09-3.01 (m, 2H), 2.05-1.88 (m, 8H), 1.78-1.66 (m, 8H); 13 C NMR δ 183.6, 174.5, 152.7, 139.7, 132.9, 129.7, 125.2, 122.5, 101.5, 44.0, 30.0, 25.8; Mass m/z 497.4 [M+1].
4-{(1E,1'E)-2-[5-(4-Hydroxy-3-methoxystyryl)-1H-pyra-zole-3-yl]vinyl}-2-methoxyphenol (4a): 1 H NMR (400 MHz, DMSO- d 6 ) δ 12.82 (brs, 1H), 9.18 (brs, 2H), 7.14 (s, 2H), 7.04 (d, J = 16.0 Hz, 2H), 6.95-6.91 (m, 4H), 6.77 (d, J = 8.0 Hz, 2H), 6.62 (s, 1H), 3.83 (s, 6H); 13 C NMR δ 157.8, 148.3, 147.2, 130.0, 129.7, 128.8, 128.2, 120.5, 116.1, 109.9, 99.7, 56.0.
4-{(1E,1'E)-2-[5-(4-Hydroxy-styryl)-1H-pyrazole-3-yl]-vinyl}-phenol (5a): 1 H NMR (400 MHz, DMSO- d 6 ) δ 12.83 (s, 1H), 9.62 (brs, 2H), 7.38 (d, J = 8.8 Hz, 4H), 6.96 (dd, J = 14.8 and 16.0 Hz, 4H), 6.79 (d, J = 8.4 Hz, 4H), 6.63 (s, 1H); 13 C NMR δ 157.7, 130.1, 129.3, 128.0, 118.5, 116.2, 112.9, 99.6.
4-{(1E,1'E)-2-[5-(4-Hydroxy-styryl)-1-(4-aminosulfonyl-phenyl)-1H-pyrazole-3-yl]vinyl}-phenol (5b): 1 H NMR (400 MHz, CDCl 3 ) δ 10.6 (brs, 2H), 8.01 (dd, J = 1.6 and 1.6 Hz, 2H), 7.75 (d, J = 1.6 and 2.0 Hz, 2H), 7.71 (d, J = 8.8 Hz, 2H), 7.44 (d, J = 8.4 Hz, 2H), 7.39 (d, J = 8.4 Hz, 2H), 7.22 (t, J = 16.0 Hz, 2H), 7.14 (s, 1H), 7.07 (d, J = 8.8 Hz, 2H), 6.97 (d, J = 16.8 Hz, 2H), 6.82-6.78 (m, 4H); 13 C NMR δ 158.6, 158.1, 152.3, 148.8, 143.2, 143.0, 142.1, 136.6, 133.7, 131.6, 128.8, 128.4, 128.1, 127.5, 127.4, 125.1, 117.1, 116.2, 113.8, 112.0, 102.0; Mass m/z 460.3 [M+1].
4-{3,5-[2-(4-Furoyloxy-3-methoxyphenyl)-vinyl]-pyrazol-1-yl}-benzenesulfonamide (6): 1 H NMR (400 MHz, Acetone- d 6 ) δ 8.12 (d, J = 8.4 Hz, 2H), 7.96 (d, J = 1.2 Hz, 2H), 7.85 (d, J = 8.8 Hz, 2H), 7.49-7.48 (m, 3H), 7.41-7.37 (m, 3H), 7.30-7.20 (m, 5H), 6.78-6.77 (m, 4H), 3.94 (s, 3H), 3.85 (s, 3H); 13 C NMR δ 169.8, 155.9, 151.8, 147.9, 147.8, 143.9, 142.9, 142.6, 142.3, 139.5, 139.1, 136.5, 135.9, 132.6, 130.5, 127.4, 124.7, 123.3, 123.2, 120.7, 119.5, 119.4, 115.8, 112.4, 111.0, 110.1, 102.6, 55.5, 48.9; Mass m/z 708.3 [M+1].
4-{3,5-Bis-[2-(4-furoyloxy-phenyl)-vinyl]-pyrazol-1-yl}-benzenesulfonamide (7): 1 H NMR (400 MHz, DMSO- d 6 ) δ 8.13 (t, J = 1.6 Hz, 2H), 8.03 (d, J = 8.8 Hz, 2H), 7.81 (d, J = 8.8 Hz, 2H), 7.74 (d, J = 8.8 Hz, 2H), 7.69 (d, J = 8.4 Hz, 2H), 7.61-7.58 (m, 2H), 7.53 (s, 2H), 7.43-7.24 (m, 8H), 7.08 (d, J = 16.4 Hz, 2H), 6.83-6.81 (m, 2H); 13 C NMR δ 156.8, 151.8, 150.3, 149.9, 149.2, 143.3, 142.8, 141.9, 135.1, 134.6, 130.6, 128.6, 128.2, 127.6, 125.3, 122.8, 120.8, 115.8, 113.3; Mass m/z 648.4 [M+1].
Acknowledgements
We are grateful to pharmacology department of the Shinpoong pharmaceutical CO., LTD. for partial support of this work.
References
Jadhav B. K. , Mahadik K. R. , Paradkar A. R. 2007 Chromatographia 65 483 -    DOI : 10.1365/s10337-006-0164-8
Guddadarangavvanahally K. , Lingamullu J. M. R. , Kunnumpurath K. 2002 J. Agric. Food. Chem. 50 3668 -    DOI : 10.1021/jf025506a
Singh R. , Rai D. , Yadav D. , Bhargava A. , Balzarrini J. , Clercq E. D. 2010 Eur. J. Med. Chem. 45 1078 -    DOI : 10.1016/j.ejmech.2009.12.002
Rajeshwar N. , Marcus P. , Stefanie L. , Karheinz B. , Sabin K. , Thomas D. , Sascha W. , Eckhard M. , Boris S. 2008 ChemMedChem. 3 165 -    DOI : 10.1002/cmdc.200700218
Claramunt R. M. , Bouissane L. , Cornago M. P. , Elguero J. , Radziwon A. , Medina C. 2009 Bioorg. Med. Chem. 17 1290 -    DOI : 10.1016/j.bmc.2008.12.029
Changtam C. , Hongmanee P. , Suksamrarn A. 2010 Eur. J. Med. Chem. 45 4446 -    DOI : 10.1016/j.ejmech.2010.07.003
Shim J. S. , Kim D. H. , Jung H. J. , Kim J. H. , Lim D. Y. , Lee S. K. , Kim K. W. , Ahn J. W. , Yoo J. S. , Rho J. R. , Shin J. H. , Kwon J. R. 2002 Bioorg. Med. Chem. 10 2987 -    DOI : 10.1016/S0968-0896(02)00129-3
Changtam C. , Koning H. P. , Ibrahim H. , Sajid M. S. 2010 Eur. J. Med. Chem. 45 941 -    DOI : 10.1016/j.ejmech.2009.11.035
Mishra S. , Narain U. , Mishra R. , Misra K. 2005 Bioorg. Chem. 13 1477 -    DOI : 10.1016/j.bmc.2004.12.057
Chen S. Y. , Chen Y. , Li Y. P. , Chen S. S. , Tan J. H. , Ou T. M. , Gu L. Q. , Huang Z. S. 2011 Bioorg. Med. Chem. 19 5596 -    DOI : 10.1016/j.bmc.2011.07.033